Avidity Biosciences, Inc.
Clinical trials sponsored by Avidity Biosciences, Inc., explained in plain language.
-
New hope for duchenne: targeted therapy now available for eligible patients
Disease control AVAILABLEThis program provides access to an experimental drug, AOC 1044, for people with Duchenne muscular dystrophy (DMD) whose genetic mutation can be treated by skipping exon 44. The goal is to help control the disease and improve muscle function. Participants must be at least 2 years …
Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Hope for FSHD: new drug enters final stage of testing
Disease control Recruiting nowThis phase 3 trial tests an experimental drug called AOC 1020 in 200 adults with facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. Participants receive either the drug or a placebo by IV infusion. The study measures muscle…
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC